Overview

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Francois Baclesse

Collaborator:

GFPC

Treatments:

Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Carboplatin
Pemetrexed